Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 6/20 | 0.41 |
| ▸ | TNF | P01375 | 3/20 | 0.40 |
| ▸ | LITAF | Q99732 | 3/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.36 |
| ▸ | MET | P08581 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.35 |
| ▸ | CRYZ | Q08257 | 1/20 | 0.35 |
| ▸ | VAT1 | Q99536 | 1/20 | 0.35 |
| ▸ | RTN4 | Q9NQC3 | 1/20 | 0.35 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21099295 | 0.90 | KRAS (0.37) | KRASTNFLITAFCCNT1CDK9 | |
| SCHEMBL21099285 | 0.90 | KRAS (0.41) | KRASTNFLITAFCCNT1CDK9 | |
| SCHEMBL21136716 | 0.90 | KRAS (0.41) | KRASTNFLITAFCCNT1CDK9 | |
| SCHEMBL21050845 | 0.85 | KRAS (0.45) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL21099594 | 0.85 | KCNH2 (0.37) | TNFLITAFCCNT1CDK9MET | |
| SCHEMBL28648177 | 0.85 | KCNH2 (0.37) | TNFLITAFCCNT1CDK9MET | |
| SCHEMBL29153252 | 0.82 | PRKCQ (0.36) | TNFLITAFCCNT1CDK9MET | |
| SCHEMBL21099583 | 0.81 | KRAS (0.63) | KRASTNFLITAFALK | |
| SCHEMBL21137320 | 0.81 | KRAS (0.43) | KRASTNFLITAFALKEGFR | |
| SCHEMBL21137338 | 0.81 | KCNH2 (0.38) | CCNT1CDK9METPRKCQPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177338-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | KRAS 272/4885TNF 2176/4885LITAF 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.